All In Biotech

Drug Trial Radar · NCT05809934

A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) With Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 220 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

220

Actual

Start

Mar 15, 2023

Primary completion

Jul 14, 2025

Study completion Sep 29, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Apr 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 given by subcutaneous injection in adult participants with non-cirrhotic non-alcoholic steatohepatitis with fibrosis and who are carriers of the PNPLA3 148M Risk Allele

Conditions

  • Nonalcoholic Steatohepatitis

Interventions

  • AZD2693Drug

    AZD2693 solution SC once per month

  • PlaceboOther

    Sodium chloride 0.9% solution SC once per month

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants Achieving NASH Resolution Without Worsening of Fibrosis Based on Histology After 52 Weeks of TreatmentTime frame: From baseline to week 54

Locations

163 sites in 22 countries. Site status is shown where the registry gives one.

  • Research Site

    Chandler, Arizona

  • Research Site

    Peoria, Arizona

  • Research Site

    Surprise, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Gardena, California

  • Research Site

    La Mesa, California

  • Research Site

    Lancaster, California

  • Research Site

    Los Angeles, California

  • Research Site

    Montclair, California

  • Research Site

    Orange, California

  • Research Site

    Rialto, California

  • Research Site

    Santa Ana, California

  • Research Site

    Boca Raton, Florida

  • Research Site

    Hialeah, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Port Orange, Florida

  • Research Site

    Winter Park, Florida

  • Research Site

    Marietta, Georgia

  • Research Site

    Topeka, Kansas

  • Research Site

    Detroit, Michigan

  • Research Site

    Las Vegas, Nevada

  • Research Site

    Westlake, Ohio

  • Research Site

    Chickasha, Oklahoma

  • Research Site

    Hershey, Pennsylvania

  • Research Site

    Summerville, South Carolina

  • Research Site

    Cordova, Tennessee

  • Research Site

    Austin, Texas

  • Research Site

    Brownsville, Texas

  • Research Site

    Denison, Texas

  • Research Site

    DeSoto, Texas

  • Research Site

    Edinburg, Texas

  • Research Site

    San Antonio, Texas

  • Research Site

    Sugar Land, Texas

  • Research Site

    Richmond, Virginia

  • Research Site

    Seattle, Washington

  • Research Site

    CABA, Argentina

  • Research Site

    CABA, Argentina

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    Córdoba, Argentina

Showing 40 of 163 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.